Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.jenburkt.com | |
Market Cap | 286.79 Cr. | |
Enterprise Value(EV) | 239.54 Cr. | 2022-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 50.20 | Trailing Twelve Months Ending 2022-09 |
Price-Earning Ratio (PE) | 12.75 | Trailing Twelve Months Ending 2022-09 |
Industry PE | 32.90 | Trailing Twelve Months Ending 2022-09 |
Book Value / Share | 278.06 | Trailing Twelve Months Ending 2022-09 |
Price to Book Value | 2.30 | Calculated using Price: 640.00 |
Dividend Yield | 1.88 | Period Ending 2022-03 |
No. of Shares Subscribed | 0.45 Cr. | 4,481,135 Shares |
FaceValue | 10 | |
Company Profile | ||
Jenburkt Pharmaceuticals Ltd, a venture to diversify into the healthcare and pharmaceutical industry, was formed in 1985 by the Bhuta family; late Hemendra N. Bhuta was the promoter of the company while the Bhuta Group was founded by Nandlal Mulji Bhuta |
1 Day |
|
-0.66% |
1 Week |
|
-1.11% |
1 Month |
|
-1.41% |
3 Month |
|
+11.76% |
6 Month |
|
+22.10% |
1 Year |
|
+5.85% |
2 Year |
|
+59.50% |
5 Year |
|
+10.34% |
10 Year |
|
+776.11% |
9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
Return on Equity (%) | 30.05 | 31.77 | 29.28 | 28.55 | 29.75 | 28.54 | 18.89 | 18.49 | 20.66 | |
Return on Capital Employed (%) | 40.94 | 42.35 | 40.17 | 39.26 | 41.99 | 36.90 | 25.73 | 23.83 | 26.89 | |
Return on Assets (%) | 16.15 | 18.40 | 18.13 | 20.10 | 22.36 | 21.99 | 14.37 | 14.68 | 16.95 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09* Rs. Cr. |
Shh. Funds | 27 | 33 | 40 | 54 | 61 | 77 | 80 | 98 | 117 | 125 | |
Non Curr. Liab. | 4 | 3 | 4 | 4 | 3 | 0 | 5 | 4 | 4 | 3 | |
Curr. Liab. | 13 | 24 | 14 | 18 | 13 | 25 | 20 | 18 | 21 | 17 | |
Minority Int. | |||||||||||
Equity & Liab. | 44 | 61 | 58 | 76 | 78 | 103 | 104 | 120 | 143 | 146 | |
Non Curr. Assets | 14 | 12 | 13 | 13 | 12 | 13 | 15 | 40 | 67 | 69 | |
Curr. Assets | 30 | 49 | 45 | 64 | 66 | 90 | 90 | 80 | 76 | 77 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 44 | 61 | 58 | 76 | 78 | 103 | 104 | 120 | 143 | 146 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2022-09 Rs. Cr. TTM |
Net Sales | 76 | 85 | 94 | 103 | 115 | 123 | 119 | 109 | 124 | 128 | |
Other Income | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 5 | 5 | |
Total Income | 78 | 87 | 96 | 106 | 118 | 126 | 123 | 114 | 129 | 133 | |
Total Expenditure | -65 | -70 | -77 | -84 | -91 | -98 | -99 | -89 | -97 | -101 | |
PBIDT | 13 | 17 | 19 | 23 | 27 | 28 | 24 | 24 | 32 | 32 | |
Interest | -1 | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 0 | 0 | |
Depreciation | -2 | -3 | -2 | -2 | -2 | -1 | -2 | -2 | -2 | -2 | |
Taxation | -3 | -5 | -6 | -7 | -8 | -7 | -6 | -5 | -8 | -7 | |
Exceptional Items | 0 | 0 | 0 | ||||||||
PAT | 8 | 10 | 11 | 14 | 17 | 20 | 15 | 17 | 22 | 22 | |
Adjusted EPS | 16 | 21 | 23 | 29 | 38 | 43 | 32 | 36 | 49 | 49 |
Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 5 | 11 | 9 | 8 | 10 | 16 | 13 | 15 | 19 | 9 | |
Cash Fr. Inv. | -1 | 0 | 1 | 0 | -10 | 1 | -11 | -3 | -19 | -1 | |
Cash Fr. Finan. | 0 | -7 | 1 | -5 | 1 | -18 | -2 | -11 | -1 | -6 | |
Net Change | 3 | 5 | 11 | 2 | 1 | -1 | 0 | 1 | 0 | 3 | |
Cash & Cash Eqvt | 11 | 17 | 28 | 30 | 2 | 1 | 1 | 3 | 2 | 5 |
Fri, 27 Jan 2023
Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares Please find enclosed the details of the daily reporting of shares brought back by the Company on 27.01.2023. |
Fri, 27 Jan 2023
Board Meeting Intimation for The Unaudited Financial Results For The Quarter And Nine Months Ended On 31St December 2022. JENBURKT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2023 inter alia to consider and approve the unaudited financial results for the quarter and nine months ended on 31st December 2022. |
Wed, 25 Jan 2023
Announcement under Regulation 30 (LODR)-Daily Buy Back of equity shares Please find enclosed the details of the daily reporting of shares brought back by the Company on 25.01.2023. |
Fri, 27 Jan 2023 |
|
|
|
|
|